A pharma company was interested in identifying novel protein-based autoimmune / auto-inflammatory assets early in development from pre-GLP studies to 18 months from an IND. The company had already conducted searches for assets along the US west coast but did not have a foothold on the East Coast or in the EU. Alacrita support was requested to identify and engage with potential partners developing assets that met the client’s search criteria.
A team of Alacrita consultants first met with the client to confirm the scouting criteria and priorities prior to conducting a search of numerous public sources such as commercial pipeline databases, SBIR grant listings, technology licensing offices, scientific literature, and venture capital websites.
As candidate assets were identified, we initiated outreach with asset owners to gain access to nonconfidential marketing materials and, upon receipt, we analyzed any preclinical data pertinent to the asset and provided the client with a high-level summary of each asset reviewed. At the end of the 3-month engagement, Alacrita provided a final draft of the asset scouting database including a list of 34 assets worthy of more detailed follow-up. We met with the client to discuss our conclusions, recommendations, and next steps.
Alacrita supports both large pharma and biotech companies with their search and evaluation activities. Our asset scouting support is often structured to integrate with the client’s internal efforts, resulting in a constant flow of new opportunities.